FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084421804> ?p ?o ?g. }

• W3084421804 endingPage "4216" @default.
• W3084421804 startingPage "4208" @default.
• W3084421804 abstract "Abstract The indicated dose of 4-factor prothrombin complex concentrate (4F-PCC) for urgent vitamin K antagonist (VKA) reversal in patients with an international normalized ratio (INR) of 2 to 4 is 25 IU/kg, but there is no indicated dose for INR &lt;2. We explored 4F-PCC dosing strategies for baseline INR &lt;2. Clinical trial data were used to develop pharmacometric models for Factor X (FX) and FII, accounting for covariates including baseline INR. FX and FII levels over time were simulated for mean baseline INR levels of the clinical trial participants plus baseline INRs 3.1, 1.9, and 1.6. For each INR, 200 virtual male patients were simulated to evaluate 4F-PCC doses of 35, 25, 20, 15, 12.5, and 10 IU/kg. Given an elevated bleeding risk with VKA therapy in Japanese vs Western populations, results were stratified by Japanese and non-Japanese patients. Target levels of FX and FII were ≥50% activity at 30 minutes after dosing in ≥80% of patients. FX- and FII-time models were developed with 1088 FX observations from 193 patients and 1074 FII observations from 192 patients. Model-based simulations indicated that at baseline INR 3.1, ≥80% of patients achieved ≥50% FX and FII activity with 25 IU/kg and 20 IU/kg 4F-PCC, respectively; at baseline INR 1.9, corresponding doses were 20 IU/kg and 15 IU/kg 4F-PCC, and at baseline INR 1.6, corresponding doses were 15 IU/kg, and 10 IU/kg 4F-PCC. Trends in Japanese and non-Japanese patients were similar. In conclusion, low 4F-PCC doses (15-20 IU/kg) may be sufficient to achieve hemostatic levels of FX and FII in Japanese and non-Japanese patients with baseline INR &lt;2." @default.
• W3084421804 created "2020-09-14" @default.
• W3084421804 creator A5010483604 @default.
• W3084421804 creator A5013142762 @default.
• W3084421804 creator A5015689408 @default.
• W3084421804 creator A5067596161 @default.
• W3084421804 creator A5070714730 @default.
• W3084421804 creator A5085131046 @default.
• W3084421804 creator A5089009870 @default.
• W3084421804 date "2020-09-08" @default.
• W3084421804 modified "2023-10-17" @default.
• W3084421804 title "Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2" @default.
• W3084421804 cites W1496174784 @default.
• W3084421804 cites W1530892454 @default.
• W3084421804 cites W1593651124 @default.
• W3084421804 cites W1977016143 @default.
• W3084421804 cites W1987422857 @default.
• W3084421804 cites W1998354077 @default.
• W3084421804 cites W2002261292 @default.
• W3084421804 cites W2014569663 @default.
• W3084421804 cites W2015696505 @default.
• W3084421804 cites W2032728138 @default.
• W3084421804 cites W2034607173 @default.
• W3084421804 cites W2042553471 @default.
• W3084421804 cites W2043573822 @default.
• W3084421804 cites W2050306424 @default.
• W3084421804 cites W2059014224 @default.
• W3084421804 cites W2070567676 @default.
• W3084421804 cites W2091399784 @default.
• W3084421804 cites W2124653669 @default.
• W3084421804 cites W2141722460 @default.
• W3084421804 cites W2142187440 @default.
• W3084421804 cites W2155155275 @default.
• W3084421804 cites W2157822705 @default.
• W3084421804 cites W2166176554 @default.
• W3084421804 cites W2214011890 @default.
• W3084421804 cites W2323559086 @default.
• W3084421804 cites W2338438098 @default.
• W3084421804 cites W2340020429 @default.
• W3084421804 cites W2341478364 @default.
• W3084421804 cites W2529445039 @default.
• W3084421804 cites W2553660708 @default.
• W3084421804 cites W2561622968 @default.
• W3084421804 cites W2604738434 @default.
• W3084421804 cites W2613891180 @default.
• W3084421804 cites W2728130785 @default.
• W3084421804 cites W2745917986 @default.
• W3084421804 cites W2771562059 @default.
• W3084421804 cites W2805266681 @default.
• W3084421804 cites W2887939111 @default.
• W3084421804 cites W2902233584 @default.
• W3084421804 cites W4238531734 @default.
• W3084421804 cites W4239414585 @default.
• W3084421804 doi "https://doi.org/10.1182/bloodadvances.2020002267" @default.
• W3084421804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7479946" @default.
• W3084421804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32898246" @default.
• W3084421804 hasPublicationYear "2020" @default.
• W3084421804 type Work @default.
• W3084421804 sameAs 3084421804 @default.
• W3084421804 citedByCount "2" @default.
• W3084421804 countsByYear W30844218042022 @default.
• W3084421804 crossrefType "journal-article" @default.
• W3084421804 hasAuthorship W3084421804A5010483604 @default.
• W3084421804 hasAuthorship W3084421804A5013142762 @default.
• W3084421804 hasAuthorship W3084421804A5015689408 @default.
• W3084421804 hasAuthorship W3084421804A5067596161 @default.
• W3084421804 hasAuthorship W3084421804A5070714730 @default.
• W3084421804 hasAuthorship W3084421804A5085131046 @default.
• W3084421804 hasAuthorship W3084421804A5089009870 @default.
• W3084421804 hasBestOaLocation W30844218041 @default.
• W3084421804 hasConcept C126322002 @default.
• W3084421804 hasConcept C2776301958 @default.
• W3084421804 hasConcept C2776704044 @default.
• W3084421804 hasConcept C2777091921 @default.
• W3084421804 hasConcept C2777288759 @default.
• W3084421804 hasConcept C2779161974 @default.
• W3084421804 hasConcept C71924100 @default.
• W3084421804 hasConcept C90924648 @default.
• W3084421804 hasConceptScore W3084421804C126322002 @default.
• W3084421804 hasConceptScore W3084421804C2776301958 @default.
• W3084421804 hasConceptScore W3084421804C2776704044 @default.
• W3084421804 hasConceptScore W3084421804C2777091921 @default.
• W3084421804 hasConceptScore W3084421804C2777288759 @default.
• W3084421804 hasConceptScore W3084421804C2779161974 @default.
• W3084421804 hasConceptScore W3084421804C71924100 @default.
• W3084421804 hasConceptScore W3084421804C90924648 @default.
• W3084421804 hasIssue "17" @default.
• W3084421804 hasLocation W30844218041 @default.
• W3084421804 hasLocation W30844218042 @default.
• W3084421804 hasOpenAccess W3084421804 @default.
• W3084421804 hasPrimaryLocation W30844218041 @default.
• W3084421804 hasRelatedWork W2000986683 @default.
• W3084421804 hasRelatedWork W2028525666 @default.
• W3084421804 hasRelatedWork W2168492365 @default.
• W3084421804 hasRelatedWork W2920756488 @default.
• W3084421804 hasRelatedWork W2924764747 @default.
• W3084421804 hasRelatedWork W2972240255 @default.
• W3084421804 hasRelatedWork W3182488367 @default.

• next